In this study, we screened our in-house library of small molecule compounds and identified that Abemaciclib, a selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor approved by FDA for breast cancer treatment [16], as the strongest inhibitor of YAP1 activity. This evidence concerns the gene YAP1 and breast cancer.